OVERVIEW FOR INVESTORS
Mandara Pharma is a global market leader in naturally occurring CBD and cannabis-based pharmaceutical research. We look forward to building impactful, lasting partnerships with investors who are ready to support our vision.
Frequently Asked Questions
Who is Mandara Pharma?
Mandarapharma Inc. is a Canadian cannabis-based pharmaceutical company led by President and CEO, Dr. Jeremy B. Desai, an internationally-renowned pharmaceutical executive with over 30 years of experience in the pharmaceutical industry.
We hold licenses in Colombia to cultivate, extract, transform and export both psychoactive and non-psychoactive cannabis plants. In fact, we currently have over 200 strains registered in Colombia, including pure strains and a number of unique strains developed by our experienced cultivators and breeders. We also hold a license in Spain to cultivate CBD-rich plants. In addition to our various R&D initiatives, we will also produce pharmaceutical-grade oil from our GMP extraction lab.
But our work goes beyond product development. We also strive to improve global economic conditions for local communities. That’s why we have created our “Social Entrepreneurship” program in Colombia, which enables indigenous, conflicted communities to participate in the legalized cannabis industry. We plan to expand our Social Entrepreneurship program to other regions around the world that suffer from similar social challenges."
What makes Mandara Pharma uniquely positioned to bring CBD brands and products to the global marketplace?
We have proven pharmaceutical experience in R&D, marketing and scale operational capacity. Our founding partner led a pharmaceutical giant with results that included $ 3B in revenue, facilities in half a dozen countries, 10,500 employees and presence in more than 100+ global markets. We have a team of world renowned cultivators with great experience, taking our plant to another level. We combine technology and integrated knowledge to develop synergistic avant-garde products with cannabis and other plants to sell in multiple markets.
How do Mandara's growing and cultivating processes create such high-quality cannabis?
Our team of renowned cannabis breeders and 212 registered strains set us above the rest.
How does Mandara's farm to pharma process ensure high-quality products?
We use a comprehensive pharma-grade, vertically-integrated production structure for all our brands. This includes a best-in-class build-up to produce extracts, isolates, soft gel capsules, bulk oil and seeds.
How does Mandara Pharma control costs with such a large, thorough operation?
Colombia is known to be the world’s second largest flower exporter. By centralizing our business here, we profit from lower production costs than if we were based somewhere like North America or Europe.
Isn't there currently 'investor fatigue' in the CBD marketplace?
When it comes to funding, we don’t take an opportunistic, short-term approach. We’re determined to find partners who want to help us build a plant-based pharmaceutical enterprise that will generate value for generations to come.
What is my reputation risk knowing recreational cannabis is still widely illegal?
Mandara is NOT in the recreational cannabis market — we are in the farm-to-pharma business. The pharmaceutical business is perhaps the most regulated business in the world and one we understand best.
Isn't Colombia an unstable environment for business?
Colombia has ideal year-round agronomic conditions, making the country a major player in the agro-export business. Colombia is a leading exporter of coffee, sugar and palm, as well as being the world's second largest cut flower exporter. Additionally, Colombia exports $300M+ of pharmaceuticals annually. The excellent weather allows us to cultivate multiple harvests and crops each year.
How does Mandara Pharma guard against unfavorable investors?
Not only does Mandara follow the ten principles of the UN Global Compact, but we also employ a due diligence framework to evaluate prospective investors. Additionally, we conduct assessments that evaluate a potential partner’s risk level as it relates to our business integrity. We use tools such as LEGALCHECK, TRANSUNION, OFAC; and applicable banking laws and regulations such as anti-money laundering (AML) and "know your customer" (KYC) legislation to evaluate potential investors.
What sets Mandara Pharma apart from other CBD companies manufacturing or distributing "Pharma-like" products?
This industry is one of the most heavily regulated in the world, and many new entrants don’t have the experience needed to design successful pharmaceutical-grade GMP facilities. To be effective requires efficient, effective, robust, and reproducible processes, from R&D to Commercial scale batches via Quality by Design and QBR.
We apply our scientific knowledge and industry experience to provide market access to approved cannabis drug products.
Isn’t CBD just another trend that will not last?
The demand for CBD is real. The industry is still evolving, though, so companies will come and go, and there will be investors who seek exceptional profits only to be disappointed. But since we’re not newcomers and we know the industry better than most, we believe companies with solid propositions and capabilities will deliver results that will boost the space of derivatives and by-products of cannabis and hemp in the coming years.